Ricasetron | 117086-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Ricasetron
• 英文别名: 3,3-dimethyl-N-[(1S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2H-indole-1-carboxamide
• CAS: 117086-68-7
• 化学式: C₁₉H₂₇N₃O
• 分子量: 313.4
• InChiKey: ILXWRFDRNAKTDD-GOOCMWNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Compositions and methods for treating synucleinopathies
  申请人：CHASE THERAPEUTICS CORPORATION

  公开号：US10799484B2

  公开（公告）日：2020-10-13

  The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.

  本发明描述了5HT3-拮抗剂与6-丙基氨基-4,5,6,7-四氢-1,3-苯并噻唑-2-胺的联合使用、以减少不良反应，促进对患有突触素病症的患者进行神经保护性治疗，从而使 6-丙基氨基-4,5,6,7-四氢-1,3-苯并噻唑-2-胺的每日剂量具有治疗效果，而不会产生普拉克索单独给药时的剂量限制性不良反应。
• Use and composition for treating myasthenia gravis and other myasthenic syndromes
  申请人：DAS-MG, Inc.

  公开号：US10842778B2

  公开（公告）日：2020-11-24

  The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrome, notably myasthenia gravis, by providing a therapeutically effective pyridostigmine bromide daily dose without the typical adverse effects.

  本发明描述了5HT3-拮抗剂与吡啶斯的明联合使用，通过提供治疗有效的吡啶斯的明溴化物日剂量，促进对患有肌无力综合征，特别是重症肌无力的哺乳动物，尤其是人、狗和猫的对症治疗，而不会产生典型的不良反应。
• COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES
  申请人：Chase Therapeutics Corporation

  公开号：EP3600291A1

  公开（公告）日：2020-02-05
• COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS
  申请人：Chase Therapeutics Corporation

  公开号：EP3856168A1

  公开（公告）日：2021-08-04
• USE AND COMPOSITION FOR TREATING MYASTHENIA GRAVIS AND OTHER MYASTHENIC SYNDROMES
  申请人：DAS-MG, INC.

  公开号：US20200054611A1

  公开（公告）日：2020-02-20

  The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrome, notably myasthenia gravis, by providing a therapeutically effective pyridostigmine bromide daily dose without the typical adverse effects.